Biphenyl

Biphenyl

SCHEMBL461631

O=C(O)c1ccccc1O.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHE

The experimentally established mechanism targets of Biphenyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.86
HPGD P15428 6/20 0.86
KDM4E B2RXH2 5/20 0.86
CA12 O43570 1/20 0.86
CA1 P00915 1/20 0.86
CA2 P00918 1/20 0.86
HMGB1 P09429 1/20 0.86
CA4 P22748 1/20 0.86
CA6 P23280 1/20 0.86
CA7 P43166 1/20 0.86
SMN1; SMN2 Q16637 1/20 0.86
CA9 Q16790 1/20 0.86
NAPRT Q6XQN6 1/20 0.86
CA14 Q9ULX7 1/20 0.86
ACMSD Q8TDX5 3/20 0.67
HNF4A P41235 3/20 0.67
DHFR P00374 1/20 0.67
MCL1 Q07820 1/20 0.67
GSTA1 P08263 1/20 0.60
ALOX15 P16050 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salicylic Acid SCHEMBL29360246 0.93 ALDH1A1 (1.00) ALDH1A1HPGDKDM4ECA12CA1
Salicylic Acid SCHEMBL29362663 0.93 ALDH1A1 (1.00) ALDH1A1HPGDKDM4ECA12CA1
Salicylic Acid SCHEMBL29606432 0.93 ALDH1A1 (1.00) ALDH1A1HPGDKDM4ECA12CA1
Salicylic Acid SCHEMBL1967 0.93 ALDH1A1 (1.00) ALDH1A1HPGDKDM4ECA12CA1
Salicylic Acid SCHEMBL1509155 0.93 ALDH1A1 (1.00) ALDH1A1HPGDKDM4ECA12CA1
Salicylic Acid SCHEMBL17156443 0.93 ALDH1A1 (1.00) ALDH1A1HPGDKDM4ECA12CA1
Salicylic Acid SCHEMBL8433746 0.93 ALDH1A1 (1.00) ALDH1A1HPGDKDM4ECA12CA1
Salicylic Acid SCHEMBL546853 0.90 ALDH1A1 (0.95) ALDH1A1HPGDKDM4ECA12CA1
Salicylic Acid SCHEMBL9691144 0.90 ALDH1A1 (0.95) ALDH1A1HPGDKDM4ECA12CA1
Salicylic Acid SCHEMBL224819 0.90 ALDH1A1 (0.95) ALDH1A1HPGDKDM4ECA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106317810-B Liquid crystal polymer composite film 财团法人工业技术研究院 2018-09-21 CN claimed
CN-106317810-B Liquid crystal polymer composite film 财团法人工业技术研究院 2018-09-21 CN disclosed
EP-2325651-B1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding SCRIPPS RESEARCH INST (US) 2014-10-08 EP disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-8168663-B2 Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof THE SCRIPPS RESEARCH INSTITUTE (US) 2012-05-01 US disclosed
US-20120065237-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2012-03-15 US disclosed
EP-1988397-B1 COMPOSITIONS AND USES FOR STABILISING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING SCRIPPS RESEARCH INST (US) 2011-09-14 EP disclosed
EP-2325651-A2 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding THE SCRIPPS RESEARCH INSTITUTE (US) 2011-05-25 EP disclosed
US-20100120919-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-05-13 US disclosed
US-20070078186-A1 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE 2007-04-05 US disclosed
EP-0976399-B1 Process for the production of a propolis extract comprising an anion-exchange step HAYASHIBARA BIOCHEM LAB (JP) 2006-04-12 EP disclosed
US-20060057644-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding SCRIPPS RESEARCH INSTITUTE, THE 2006-03-16 US disclosed
EP-1587821-A2 COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING The Scripps Research Institute (US) 2005-10-26 EP disclosed
US-20040152140-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding THE SCRIPPS RESEARCH INSTITUTE 2004-08-05 US disclosed
WO-2004056315-A2 COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING THE SCRIPPS RESEARCH INSTITUTE (US) 2004-07-08 WO disclosed
US-6153228-A A DEODORIZED PROPOLIS EXTRACT WHEREIN THE AMOUNT OF AT LEAST ONE ODORIZING INGREDIENT IS REDUCED; TESTING USING GAS CHROMATOGRAPHY; COSMETICS; DRUGS; FOODS KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2000-11-28 US disclosed
US-6153227-A REDUCING THE ODOR BY SOAKING PROPOLIS IN A HYDROPHILIC SOLVENT, E.G., METHANOL, TO EFFECT EXTRACTION FOLLOWED BY TREATING THE LIQUID LAYER WITH AN ANION EXCHANGE RESIN; WITHOUT ATTENUATING THE INHERENT BIOLOGICAL ACTIVITIES KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2000-11-28 US disclosed
EP-0976399-A1 Propolis extract KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2000-02-02 EP disclosed
CN-1067913-A Polymer composites of thermoplasticity and liquid crystalline polymers and preparation method thereof BP AMERICA (US) 1993-01-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078186-A1 Methods for treating transthyretin amyloid diseases TTR, TTPA, PRNP ALDH1A1 2744/4885HPGD 2551/4885KDM4E 4518/4885
US-20120065237-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES TTR, TTPA, PRNP ALDH1A1 2744/4885HPGD 2551/4885KDM4E 4518/4885
US-20100120919-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES TTR, TTPA, PRNP ALDH1A1 2744/4885HPGD 2551/4885KDM4E 4518/4885
US-20060057644-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding TTR, TTPA, PRNP ALDH1A1 3491/4885HPGD 3422/4885KDM4E 4544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.